1. Home
  2. CNEY vs MBIO Comparison

CNEY vs MBIO Comparison

Compare CNEY & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CN Energy Group Inc.

CNEY

CN Energy Group Inc.

HOLD

Current Price

$0.85

Market Cap

5.9M

Sector

Industrials

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.74

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNEY
MBIO
Founded
2009
2015
Country
China
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
5.1M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
CNEY
MBIO
Price
$0.85
$0.74
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.8M
57.6K
Earning Date
02-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.53
52 Week High
$3.04
$7.00

Technical Indicators

Market Signals
Indicator
CNEY
MBIO
Relative Strength Index (RSI) 42.12 61.11
Support Level $0.53 $0.69
Resistance Level $1.07 $0.80
Average True Range (ATR) 0.34 0.07
MACD -0.09 0.01
Stochastic Oscillator 1.46 87.70

Price Performance

Historical Comparison
CNEY
MBIO

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: